Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
New England Journal of Medicine · 25.09.2025 · 393 (12) · 1177-1190
DOI: 10.1056/nejmoa2504341 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 25.09.2025. Verfasst von Talha Munir und 35 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Cancer Research UK, Johnson & Johnson, Pharmacyclics.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
- Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds, United Kingdom.
- Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
- University of Manchester, Manchester, United Kingdom.
- Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.
- University College London Hospitals NHS Foundation Trust, London.
ORCID-Profile: Lelia Duley
Förderung
- Cancer Research UK
- Johnson & Johnson
- Pharmacyclics
- AbbVie
Zitieren
APA
Munir, T., Girvan, S., Cairns, D. A., Bloor, A., Allsup, D., Varghese, A. M., Gohil, S., Paneesha, S., Pettitt, A., Eyre, T., Fox, C. P., Forconi, F., Kennedy, B., Balotis, C., Pemberton, N., Sheehy, O., Gribben, J., Elmusharaf, N., Gatto, S., …, & UK CLL Trials Group (2025). Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 393(12), 1177-1190. https://doi.org/10.1056/nejmoa2504341
Vancouver
Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2025;393(12):1177-1190. doi:10.1056/nejmoa2504341
BibTeX
@article{Munir2025,
author = {Munir, Talha and Girvan, Sean and Cairns, David A and Bloor, Adrian and Allsup, David and Varghese, Abraham M and Gohil, Satyen and Paneesha, Shankara and Pettitt, Andrew and Eyre, Toby and Fox, Christopher P and Forconi, Francesco and Kennedy, Ben and Balotis, Constantine and Pemberton, Nicholas and Sheehy, Oonagh and Gribben, John and Elmusharaf, Nagah and Gatto, Simona and Preston, Gavin and Schuh, Anna and Walewska, Renata and Duley, Lelia and Webster, Nichola and Dalal, Surita and Rawstron, Andrew and Howard, Dena and Hockaday, Anna and Jackson, Sharon and Greatorex, Natasha and Bell, Sue and Stones, David and Brown, Julia M and Patten, Piers E M and Hillmen, Peter and UK CLL Trials Group, UK CLL Trials Group},
title = {Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {12},
pages = {1177--1190},
doi = {10.1056/nejmoa2504341}
}
EUVIMED